Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;511(1):251-254.
doi: 10.1134/S0012496623700412. Epub 2023 Oct 13.

Higher Infectivity of the Human Immunodeficiency Virus in Sensitive Cells with a Modification of the CCR5 Gene

D N Nosik  1 , L B Kalnina  2 , L M Selimova  2 , A V Pronin  2
Affiliations

Higher Infectivity of the Human Immunodeficiency Virus in Sensitive Cells with a Modification of the CCR5 Gene

D N Nosik et al. Dokl Biol Sci. 2023 Aug.

Abstract

As a natural mutation of the human ccr5 gene has been shown to confer resistance to human immunodeficiency virus type 1 (HIV-1) infection, a new avenue has opened in the development of alternative treatment approaches through genome editing. One of the two chemokine co-receptors of the plasma membrane is utilized by HIV-1 to infect CD4+ cells. HIV-1 strains that utilize CCR5 circulate in early infection, and strains that utilize CXCR4 circulate at advanced stages. A complex relationship may exist in the expression regulation of the receptors and may affect virus replication in cells that normally do not express CCR5 on the membrane, such as the MT-4 cell line. MT-4 cells were used to study the effect of ccr5 modification HIV-1 replication in vitro. Genetic modification of ccr5 in MT-4 cells was shown to increase the activities of HIV-1 strains, especially in homozygote. The results indicate that genome editing should be performed with caution in human cells and that the issue needs comprehensive investigation.

Keywords: CCR5; CXCR4; MT-4 cells; human immunodeficiency virus type 1 (HIV-1).

PubMed Disclaimer

References

REFERENCES

    1. Allen, A.G., Chung, C.H., Atkins, A., et al., Gene editing of HIV-1 co-receptors to prevent and/or cure virus infection, Front. Microbiol., 2018, vol. 9, pp. 2940–2953. - DOI - PubMed - PMC
    1. Allers, K., Hutter, G., Hofmann, J., et al., Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation, Blood, 2011, vol. 117, pp. 2791–2799. - DOI - PubMed
    1. Drake, M.J. and Bates, P., Application of gene editing technologies to HIV-1, Curr. Opin. HIV AIDS, 2015, vol. 10, no. 2, pp. 123–127. - DOI - PubMed - PMC
    1. Miyoshi, I., Kubonishi, I., Yoshimoto, S., et al., Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells, Nature, 1981, vol. 294, pp. 770–771. - DOI - PubMed
    1. Manns, A., Hisada, M., and La Grenade, L., Human T-lymphotropic virus type I infection, Lancet, 1999, vol. 353, pp. 1951–1958. - DOI - PubMed

LinkOut - more resources